Advertisement

Index by author

November 01, 1994; Volume 22,Issue 6

A

  1. Alton, K B

    1. Urinary metabolites of (R),(R)-labetalol.
      K B Alton, T M Chan and B N Pramanik
      Drug Metabolism and Disposition November 1994, 22 (6) 866-872;

  2. Anders, M W

    1. Tissue distribution and stereoselectivity of remacemide-glycine hydrolase.
      H Heyn, Y G Bankmann and M W Anders
      Drug Metabolism and Disposition November 1994, 22 (6) 973-974;

  3. Ardouin, T

    1. Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

B

  1. Babu, S R

    1. Glucuronidation of N-acetylbenzidine by human liver.
      S R Babu, V M Lakshmi, T V Zenser and B B Davis
      Drug Metabolism and Disposition November 1994, 22 (6) 922-927;

  2. Bankmann, Y G

    1. Tissue distribution and stereoselectivity of remacemide-glycine hydrolase.
      H Heyn, Y G Bankmann and M W Anders
      Drug Metabolism and Disposition November 1994, 22 (6) 973-974;

  3. Barnett, J L

    1. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;

  4. Boelsterli, U A

    1. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct.
      A Kretz-Rommel and U A Boelsterli
      Drug Metabolism and Disposition November 1994, 22 (6) 956-961;

  5. Bonner, H S

    1. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
      L M Shaw, H S Bonner and D Q Brown
      Drug Metabolism and Disposition November 1994, 22 (6) 895-902;

  6. Boyd, S A

    1. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;

  7. Brennan, J M

    1. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
      F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
      Drug Metabolism and Disposition November 1994, 22 (6) 835-842;

  8. Brown, D Q

    1. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
      L M Shaw, H S Bonner and D Q Brown
      Drug Metabolism and Disposition November 1994, 22 (6) 895-902;

  9. Brown, R P

    1. A comprehensive evaluation of the vial equilibration method for quantification of the metabolism of volatile organic chemicals. Trichloroethylene.
      C Kim, R O Manning, R P Brown and J V Bruckner
      Drug Metabolism and Disposition November 1994, 22 (6) 858-865;

  10. Bruckner, J V

    1. A comprehensive evaluation of the vial equilibration method for quantification of the metabolism of volatile organic chemicals. Trichloroethylene.
      C Kim, R O Manning, R P Brown and J V Bruckner
      Drug Metabolism and Disposition November 1994, 22 (6) 858-865;

C

  1. Carde, P

    1. Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

  2. Cepa, S

    1. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;

  3. Chan, T M

    1. Urinary metabolites of (R),(R)-labetalol.
      K B Alton, T M Chan and B N Pramanik
      Drug Metabolism and Disposition November 1994, 22 (6) 866-872;

  4. Chauret, N

    1. Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;

  5. Coddington, A B

    1. Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
      L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
      Drug Metabolism and Disposition November 1994, 22 (6) 903-908;

  6. Colby, H D

    1. Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
      L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
      Drug Metabolism and Disposition November 1994, 22 (6) 903-908;

  7. Crawford, K

    1. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
      M Jurima-Romet, K Crawford, T Cyr and T Inaba
      Drug Metabolism and Disposition November 1994, 22 (6) 849-857;

  8. Cribb, A E

    1. Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;

  9. Cyr, T

    1. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
      M Jurima-Romet, K Crawford, T Cyr and T Inaba
      Drug Metabolism and Disposition November 1994, 22 (6) 849-857;

D

  1. Davis, B B

    1. Glucuronidation of N-acetylbenzidine by human liver.
      S R Babu, V M Lakshmi, T V Zenser and B B Davis
      Drug Metabolism and Disposition November 1994, 22 (6) 922-927;

  2. Dehal, S S

    1. Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B.
      S S Dehal and D Kupfer
      Drug Metabolism and Disposition November 1994, 22 (6) 937-946;

  3. Denissen, J F

    1. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;

  4. Deschamps de Paillette, E

    1. Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

E

  1. Ehlers, K

    1. Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;

  2. Elmazar, M M

    1. Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;

  3. Ezan, E

    1. Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

G

  1. Grabowski, B A

    1. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;

  2. Griffin, G P

    1. Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;

  3. Grognet, J M

    1. Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

H

  1. Hall, S D

    1. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;

  2. Hamilton, T C

    1. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
      F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
      Drug Metabolism and Disposition November 1994, 22 (6) 835-842;

  3. Hamman, M A

    1. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;

  4. Hara, K

    1. In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes.
      T Hasegawa, K Hara, T Kenmochi and S Hata
      Drug Metabolism and Disposition November 1994, 22 (6) 916-921;

  5. Hasegawa, T

    1. In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes.
      T Hasegawa, K Hara, T Kenmochi and S Hata
      Drug Metabolism and Disposition November 1994, 22 (6) 916-921;

  6. Hata, S

    1. In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes.
      T Hasegawa, K Hara, T Kenmochi and S Hata
      Drug Metabolism and Disposition November 1994, 22 (6) 916-921;

  7. Heyn, H

    1. Tissue distribution and stereoselectivity of remacemide-glycine hydrolase.
      H Heyn, Y G Bankmann and M W Anders
      Drug Metabolism and Disposition November 1994, 22 (6) 973-974;

  8. Hill, P

    1. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;

  9. Hirata, K

    1. Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
      M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
      Drug Metabolism and Disposition November 1994, 22 (6) 889-894;

  10. Horie, T

    1. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;

  11. Hosokawa, M

    1. Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
      M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
      Drug Metabolism and Disposition November 1994, 22 (6) 889-894;

  12. Hosokawa, S

    1. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;

I

  1. Inaba, T

    1. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
      M Jurima-Romet, K Crawford, T Cyr and T Inaba
      Drug Metabolism and Disposition November 1994, 22 (6) 849-857;

  2. Isnard, F

    1. Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

J

  1. Jackson, B J

    1. Theophylline N-demethylations as probes for P4501A1 and P4501A2.
      M A Sarkar and B J Jackson
      Drug Metabolism and Disposition November 1994, 22 (6) 827-834;

  2. Johnson, M K

    1. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;

  3. Jurima-Romet, M

    1. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
      M Jurima-Romet, K Crawford, T Cyr and T Inaba
      Drug Metabolism and Disposition November 1994, 22 (6) 849-857;

K

  1. Kenmochi, T

    1. In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes.
      T Hasegawa, K Hara, T Kenmochi and S Hata
      Drug Metabolism and Disposition November 1994, 22 (6) 916-921;

  2. Kim, C

    1. A comprehensive evaluation of the vial equilibration method for quantification of the metabolism of volatile organic chemicals. Trichloroethylene.
      C Kim, R O Manning, R P Brown and J V Bruckner
      Drug Metabolism and Disposition November 1994, 22 (6) 858-865;

  3. Kitada, M

    1. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;

  4. Kolars, J C

    1. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;

  5. Kretz-Rommel, A

    1. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct.
      A Kretz-Rommel and U A Boelsterli
      Drug Metabolism and Disposition November 1994, 22 (6) 956-961;

  6. Kunze, K L

    1. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;

  7. Kupfer, D

    1. Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B.
      S S Dehal and D Kupfer
      Drug Metabolism and Disposition November 1994, 22 (6) 937-946;

L

  1. Lacreta, F P

    1. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
      F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
      Drug Metabolism and Disposition November 1994, 22 (6) 835-842;

  2. Lakshmi, V M

    1. Glucuronidation of N-acetylbenzidine by human liver.
      S R Babu, V M Lakshmi, T V Zenser and B B Davis
      Drug Metabolism and Disposition November 1994, 22 (6) 922-927;

  3. Lee, C

    1. Identification of hepatocytes as the major locus of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1-related P450s, TCDDAA and TCDDAHH, in chick embryo liver.
      L Paroli, C Lee and A B Rifkind
      Drug Metabolism and Disposition November 1994, 22 (6) 962-968;

  4. Le Kerneau, J

    1. Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

  5. Linhart, I

    1. Solvolysis of butadiene monoxide.
      I Linhart
      Drug Metabolism and Disposition November 1994, 22 (6) 820-821;

  6. Los, L E

    1. Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
      L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
      Drug Metabolism and Disposition November 1994, 22 (6) 903-908;

  7. Lown, K S

    1. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;

M

  1. Mangold, J B

    1. Pharmacokinetics and metabolism of cyclosporin G in humans.
      J B Mangold, H F Schran and F L Tse
      Drug Metabolism and Disposition November 1994, 22 (6) 873-879;

  2. Manning, R O

    1. A comprehensive evaluation of the vial equilibration method for quantification of the metabolism of volatile organic chemicals. Trichloroethylene.
      C Kim, R O Manning, R P Brown and J V Bruckner
      Drug Metabolism and Disposition November 1994, 22 (6) 858-865;

  3. Masubuchi, Y

    1. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;

N

  1. Nakata, F

    1. Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
      M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
      Drug Metabolism and Disposition November 1994, 22 (6) 889-894;

  2. Narimatsu, S

    1. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;

  3. Nau, H

    1. Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;

  4. Nicoll-Griffith, D A

    1. Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;

O

  1. O'Dwyer, P J

    1. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
      F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
      Drug Metabolism and Disposition November 1994, 22 (6) 835-842;

  2. Ohmori, S

    1. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;

  3. Ozols, R F

    1. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
      F P Lacreta, J M Brennan, T C Hamilton, R F Ozols and P J O'Dwyer
      Drug Metabolism and Disposition November 1994, 22 (6) 835-842;

P

  1. Paroli, L

    1. Identification of hepatocytes as the major locus of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1-related P450s, TCDDAA and TCDDAHH, in chick embryo liver.
      L Paroli, C Lee and A B Rifkind
      Drug Metabolism and Disposition November 1994, 22 (6) 962-968;

  2. Pitzenberger, S M

    1. Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
      L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
      Drug Metabolism and Disposition November 1994, 22 (6) 903-908;

  3. Pramanik, B N

    1. Urinary metabolites of (R),(R)-labetalol.
      K B Alton, T M Chan and B N Pramanik
      Drug Metabolism and Disposition November 1994, 22 (6) 866-872;

R

  1. Ramjit, H G

    1. Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
      L E Los, S M Pitzenberger, H G Ramjit, A B Coddington and H D Colby
      Drug Metabolism and Disposition November 1994, 22 (6) 903-908;

  2. Rettie, A E

    1. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;

  3. Rifkind, A B

    1. Identification of hepatocytes as the major locus of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1-related P450s, TCDDAA and TCDDAHH, in chick embryo liver.
      L Paroli, C Lee and A B Rifkind
      Drug Metabolism and Disposition November 1994, 22 (6) 962-968;

  4. Rushmore, T H

    1. Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;

S

  1. Sarkar, M A

    1. Theophylline N-demethylations as probes for P4501A1 and P4501A2.
      M A Sarkar and B J Jackson
      Drug Metabolism and Disposition November 1994, 22 (6) 827-834;

  2. Sass, J O

    1. Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;

  3. Satoh, T

    1. Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
      M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
      Drug Metabolism and Disposition November 1994, 22 (6) 889-894;

  4. Schran, H F

    1. Pharmacokinetics and metabolism of cyclosporin G in humans.
      J B Mangold, H F Schran and F L Tse
      Drug Metabolism and Disposition November 1994, 22 (6) 873-879;

  5. Semple, H A

    1. Propranolol disposition in the single-pass isolated, perfused rat liver in the presence and absence of insulin and glucagon.
      H A Semple and F Xia
      Drug Metabolism and Disposition November 1994, 22 (6) 822-826;

  6. Shaw, L M

    1. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
      L M Shaw, H S Bonner and D Q Brown
      Drug Metabolism and Disposition November 1994, 22 (6) 895-902;

  7. Spielberg, S P

    1. Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.
      A E Cribb, G P Griffin, S P Spielberg, T H Rushmore, N Chauret and D A Nicoll-Griffith
      Drug Metabolism and Disposition November 1994, 22 (6) 969-972;

  8. Stein, H

    1. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;

  9. Suga, T

    1. Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator.
      M Hosokawa, K Hirata, F Nakata, T Suga and T Satoh
      Drug Metabolism and Disposition November 1994, 22 (6) 889-894;

  10. Suzuki, T

    1. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
      Y Masubuchi, S Hosokawa, T Horie, T Suzuki, S Ohmori, M Kitada and S Narimatsu
      Drug Metabolism and Disposition November 1994, 22 (6) 909-915;

T

  1. Thomas, F

    1. Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis.
      E Ezan, P Carde, J Le Kerneau, T Ardouin, F Thomas, F Isnard, E Deschamps de Paillette and J M Grognet
      Drug Metabolism and Disposition November 1994, 22 (6) 843-848;

  2. Thummel, K E

    1. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;

  3. Trager, W F

    1. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;

  4. Tse, F L

    1. Pharmacokinetics and metabolism of cyclosporin G in humans.
      J B Mangold, H F Schran and F L Tse
      Drug Metabolism and Disposition November 1994, 22 (6) 873-879;

  5. Tzimas, G

    1. Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;

U

  1. Uchic, J T

    1. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans.
      J F Denissen, B A Grabowski, M K Johnson, S A Boyd, J T Uchic, H Stein, S Cepa and P Hill
      Drug Metabolism and Disposition November 1994, 22 (6) 880-888;

V

  1. Vandenbranden, M

    1. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;

W

  1. Watkins, P B

    1. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;

  2. Wienkers, L C

    1. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;

  3. Wittfoht, W

    1. Identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-cis-retinoic acid and limited transfer of 9-cis-retinoic acid and 9,13-dicis-retinoic acid to the mouse and rat embryos.
      G Tzimas, J O Sass, W Wittfoht, M M Elmazar, K Ehlers and H Nau
      Drug Metabolism and Disposition November 1994, 22 (6) 928-936;

  4. Wrighton, S A

    1. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
      K S Lown, J C Kolars, K E Thummel, J L Barnett, K L Kunze, S A Wrighton and P B Watkins
      Drug Metabolism and Disposition November 1994, 22 (6) 947-955;
    2. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
      S D Hall, M A Hamman, A E Rettie, L C Wienkers, W F Trager, M Vandenbranden and S A Wrighton
      Drug Metabolism and Disposition November 1994, 22 (6) 975-978;

X

  1. Xia, F

    1. Propranolol disposition in the single-pass isolated, perfused rat liver in the presence and absence of insulin and glucagon.
      H A Semple and F Xia
      Drug Metabolism and Disposition November 1994, 22 (6) 822-826;

Z

  1. Zenser, T V

    1. Glucuronidation of N-acetylbenzidine by human liver.
      S R Babu, V M Lakshmi, T V Zenser and B B Davis
      Drug Metabolism and Disposition November 1994, 22 (6) 922-927;
Back to top

In this issue

Advertisement